Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation (GERN) is a clinical-stage biopharmaceutical company advancing novel oncology therapies through its telomerase inhibitor research. This page provides investors and industry professionals with verified updates on clinical developments, regulatory milestones, and strategic initiatives.
Access the latest press releases and analysis related to imetelstat's progress in treating hematologic malignancies like myelodysplastic syndromes. Our curated collection ensures you stay informed about trial results, partnership announcements, and scientific presentations without speculative commentary.
Key updates include details on Phase 3 clinical trials, FDA communications, intellectual property developments, and collaboration agreements. All content is sourced directly from official company channels to maintain accuracy and compliance.
Bookmark this page for streamlined access to Geron's evolving story in cancer therapeutics. Check back regularly for objective reporting on advancements in telomerase-targeted treatment approaches.
Geron (Nasdaq: GERN), a commercial-stage biopharmaceutical company, has announced that it will release its second quarter 2024 financial results and business highlights on Thursday, August 8, 2024. The company will issue a press release before the market opens, which will be available on their website. Additionally, Geron will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the financial results and business highlights. Interested parties can access the webcast by registering online through the provided link. An archive of the webcast will be available on the company's website for 30 days following the event.
Geron , a biopharmaceutical company, announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The company granted non-statutory stock options for 222,660 shares to new employees as of June 19, 2024. The exercise price is $4.49 per share, equal to the closing price of Geron stock on the grant date. These options have a 10-year term and vest over four years, with 12.5% vesting after six months and the remainder vesting in equal installments over 42 months, subject to continued employment. The grants are part of Geron's 2018 Inducement Award Plan.
Geron has announced FDA approval for RYTELO™ (imetelstat), the first telomerase inhibitor, to treat adults with lower-risk myelodysplastic syndromes (MDS) suffering from transfusion-dependent anemia. The approval covers ESA ineligible and relapsed/refractory patients, regardless of ring sideroblast status. The IMerge Phase 3 clinical trial revealed significant improvements in transfusion independence and hemoglobin levels. The common Grade 3/4 adverse reactions were thrombocytopenia and neutropenia but were generally manageable. A conference call is scheduled for June 7, 2024, at 8 am ET to discuss these developments.
Geron (Nasdaq: GERN) announced the grant of non-statutory stock options to purchase 2,910,780 shares of common stock as inducements for newly hired employees. The options were granted on May 15, 2024, at an exercise price of $3.90 per share, matching the closing price on the grant date. The options, which have a 10-year term, will vest over four years, starting with 12.5% on the six-month anniversary of employment, followed by equal monthly installments over the next 42 months. These inducements are in line with Nasdaq Listing Rule 5635(c)(4) and Geron's 2018 Inducement Award Plan.
Geron (Nasdaq: GERN) reported financial results for the first quarter of 2024, including a net loss of $55.4 million and revenues of $304,000. The company has completed commercial team onboarding and is preparing for the potential U.S. launch of imetelstat pending FDA approval. The Phase 3 IMpactMF trial continues with updated timelines. Geron expects total operating expenses for fiscal year 2024 to be $270-280 million.
FAQ
What is the current stock price of Geron (GERN)?
What is the market cap of Geron (GERN)?
